EUVIMEDEUVIMED entdecken
Crossref

Evaluating the antibacterial activity of ceftazidime/avibactam and aztreonam combinations against multidrug-resistant Stenotrophomonas maltophilia complex isolates in a hollow fibre infection model

Quentin Vallé, Rajnikant Sharma, Ngoc Minh Bui, Ashley Schaefer, Ramya Mahadevan, Maria F Mojica, Adrian Khoei, Amy Mathers, Romney M Humphries, Thomas H Clarke, Derrick Fouts, John J LiPuma und 3 weitere

Clinical Microbiology and Infection · 2026

DOI: 10.1016/j.cmi.2026.02.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Quentin Vallé und 14 weiteren Autor:innen. Beteiligte Einrichtung: USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: AbbVie, Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Stenotrophomonas maltophilia is a multidrug-resistant Gram-negative pathogen causing serious infections in vulnerable populations, including individuals with cystic fibrosis and immunocompromised patients. We evaluated the activity of aztreonam (ATM) and ceftazidime/avibactam (CZA) against S. maltophilia complex (Smc) isolates. METHODS: Interactions between ATM and CZA were evaluated using static concentration time-kill assays across 11 Smc isolates. A mechanism-based pharmacokinetic/pharmacodynamic model was developed to characterize bacterial killing dynamics and guide regimen selection. Selected regimens were then evaluated in the hollow fibre infection model under clinically relevant drug exposures. Emergence of resistance was assessed via population analysis profiles, and scanning electron microscopy visualized antibiotic-induced morphological changes. RESULTS: Clinically relevant ATM + CZA exposures produced 31-74% reduction in area under the log-transformed bacterial count versus time curve across all Smc isolates in static concentration time-kill assays. In the hollow fibre infection model, ATM + CZA achieved ≥3-log10 CFU/mL reduction at 24 hours from an initial ∼7.5-log10 CFU/mL inoculum. This effect was sustained over 168 hours against GG6 strain. Against the non-GG6 strain, both continuous-infusion and standard-dosing regimens showed ∼2-log10 regrowth after 72 hours, but overall suppressed resistant subpopulations more effectively than trimethoprim/sulfamethoxazole. CONCLUSIONS: Smc infections remain challenging because of intrinsic resistance mechanisms. These findings demonstrate the therapeutic potential of ATM + CZA, and support further evaluation using murine pneumonia and bacteraemia models of S. maltophilia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stenotrophomonas maltophiliaCeftazidimeAzabicyclo CompoundsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialAztreonamGram-Negative Bacterial InfectionsDrug CombinationsMicrobial Sensitivity TestsHumans

Stichwörter der Autor:innen

Beta lactam MDRCeftazidimeCombinationMechanism-based modellingPK/PDPharmacodynamicsPharmacokineticsResistanceStenotrophomonas maltophilia complex

Substanzen

CeftazidimeAzabicyclo CompoundsAnti-Bacterial AgentsDrug Combinationsavibactam, ceftazidime drug combinationAztreonam

Autor:innen und Institutionen

  • USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
  • The University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, NC, USA.
  • Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA; Case VA Center fo…
  • Department of Medicine and Pathology, School of Medicine, University of Virginia, Charlottesville, VA, USA.
  • Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • J. Craig Venter Institute, Rockville, MD, USA.

Förderung

  • AbbVie
  • Merck

Zitieren

APA

Vallé, Q., Sharma, R., Bui, N. M., Schaefer, A., Mahadevan, R., Mojica, M. F., Khoei, A., Mathers, A., Humphries, R. M., Clarke, T. H., Fouts, D., LiPuma, J. J., van Duin, D., Bonomo, R. A., & Rao, G. G. (2026). Evaluating the antibacterial activity of ceftazidime/avibactam and aztreonam combinations against multidrug-resistant Stenotrophomonas maltophilia complex isolates in a hollow fibre infection model. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2026.02.010

Vancouver

Vallé Q, Sharma R, Bui NM, Schaefer A, Mahadevan R, Mojica MF, et al. Evaluating the antibacterial activity of ceftazidime/avibactam and aztreonam combinations against multidrug-resistant Stenotrophomonas maltophilia complex isolates in a hollow fibre infection model. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2026.02.010

BibTeX
@article{Vall2026,
  author = {Vallé, Quentin and Sharma, Rajnikant and Bui, Ngoc Minh and Schaefer, Ashley and Mahadevan, Ramya and Mojica, Maria F and Khoei, Adrian and Mathers, Amy and Humphries, Romney M and Clarke, Thomas H and Fouts, Derrick and LiPuma, John J and van Duin, David and Bonomo, Robert A and Rao, Gauri G},
  title = {Evaluating the antibacterial activity of ceftazidime/avibactam and aztreonam combinations against multidrug-resistant Stenotrophomonas maltophilia complex isolates in a hollow fibre infection model},
  journal = {Clinical Microbiology and Infection},
  year = {2026},
  doi = {10.1016/j.cmi.2026.02.010}
}
Kostenlos starten →